The Peptide Field. Abaloparatide: approval and evidence record.

Editorial review: 2026-07-23. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/abaloparatide

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=abaloparatide#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: An FDA-approved product exists for defined osteoporosis populations

Exact product limits: The study result belongs to the named prescription product, not every similar product or use. Tymlos is a product-specific prescription medicine. Trial findings do not validate unapproved PTHrP analogues or general performance use.

Human outcomes: Strong. The ACTIVE phase 3 trial supports fracture-risk reduction in postmenopausal women with osteoporosis.

Body effects in people: Strong. Approved labeling characterizes PTH1-receptor activity, exposure, and bone-turnover effects.

What the evidence shows: The ACTIVE study compared abaloparatide with placebo or open-label teriparatide in postmenopausal women with osteoporosis. Abaloparatide reduced new spine and non-spine fractures versus placebo over 18 months.

What remains unknown: The result does not establish that it is better than every osteoporosis medicine, improves healthy people, or heals every new injury better.

Safety limits: This prescription osteoporosis medicine has product-specific warnings and limits on use. No dose, injection, or performance guidance is provided.

Product record: Tymlos. Form: Injection pen. Route: Subcutaneous.
Scope: Osteoporosis uses in the high-fracture-risk populations defined in the product label.
Published label: 2025 label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208743Orig1s017lbl.pdf

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. TYMLOS (abaloparatide) prescribing information. 2025. Accessed 2026-07-23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208743Orig1s017lbl.pdf

PubMed · JAMA. Abaloparatide vs placebo on new vertebral fractures: ACTIVE. 2016. Accessed 2026-07-23. https://pubmed.ncbi.nlm.nih.gov/27533157/

U.S. Food and Drug Administration. Drug approvals and databases. 2026. Accessed 2026-07-23. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

Keep the limits, review date, and sources with this record. Check the current source for changes.